The United States Dollars Series Food and Drug Administration (FDA) announced that it has approved the first vaccine developed by BioMarin with positive results against achondroplasia , which is one of the most common causes of dwarfism.
Euronews reported that the drug Voxzogo , which was approved and made available on Friday, is up to 1.6 centimeters per year in children treated compared to patients who were administered daily and given placebo in clinical tesdollarser. It has been reported that it provides height increase.
Children who are treated can have almost the same height as their yellows
In its statement, the developer company BioMarin; He noted that it is possible for people with achondroplasia to reach almost the same height as non-sick -year-olds if they are treated with Voxzogo during childhood. “There is no question mark about the medicine making a big difference for patients” , BioMarin General Manager stated that the main difference is daily things like driving or not, and being able to reach items in cupboards .
The annual treatment fee is determined as 320 thousand dollars , and the number of potential buyer patients in the USA is 3 thousand. The company is expected to generate revenue of up to $1 billion annually from this new drug.
No information was shared about whether the Voxzogo treatment developed against achondroplasia provides any protection against life-threatening factors such as hearing loss, sleep apnea and skeletal problems due to the disease.
0 Comments